{{Rsnum
|rsid=187116
|Gene=CD44
|Chromosome=11
|position=35144253
|Orientation=minus
|GMAF=0.4683
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=CD44
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 31.9 | 46.0 | 22.1
| HCB | 34.3 | 51.1 | 14.6
| JPT | 45.1 | 37.2 | 17.7
| YRI | 1.4 | 20.4 | 78.2
| ASW | 5.3 | 38.6 | 56.1
| CHB | 34.3 | 51.1 | 14.6
| CHD | 36.7 | 45.0 | 18.3
| GIH | 37.6 | 37.6 | 24.8
| LWK | 1.8 | 30.9 | 67.3
| MEX | 22.4 | 55.2 | 22.4
| MKK | 8.3 | 43.6 | 48.1
| TSI | 22.5 | 52.9 | 24.5
| HapMapRevision=28
}}

[[rs187116]], also known as +4883G>A, is a SNP in the [[CD44]] gene.

A presentation at the 2010 American Society of Clinical Oncology meeting based on ~100 patients reported this SNP as being significantly associated with more aggressive [[gastric cancer]]. In dbSNP orientation, the risk allele is [[rs187116]](C); patients carrying at least one [[rs187116]](C) had a significantly shorter median time-to-recurrence (TTR) of 2.1 years compared to 7.0 years TTR for [[rs187116]](T;T) patients (p = 0.036, log-rank test).[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=1689]

{{PMID Auto
|PMID=21105049
|Title=Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma.
|OA=1
}}

{{PMID Auto
|PMID=22710270
|Title=Pooling/bootstrap-based GWAS (pbGWAS) identifies new loci modifying the age of onset in PSEN1 p.Glu280Ala Alzheimer's disease.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}